OH2
Phase 3Small molecule
OH2 is one of 166 small molecule programs targeting Liver Cancer. It is currently in Phase 3.
5
Indications
11
Total Trials
6
Active Trials
165
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
177 competitors in Melanoma
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Lenvima
EisaiPhase 3
Libtayo
RegeneronPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bladder Cancer2 trials
4 more indications
Liver Cancer1 trial
Solid Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OH2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details